UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 25, 2007
Gen-Probe Incorporated
(Exact Name of Registrant as Specified in Charter)
| |
|
|
|
|
| Delaware
|
|
001-31279
|
|
33-0044608 |
| (State or Other Jurisdiction of
|
|
(Commission
|
|
(I.R.S. Employer |
| Incorporation)
|
|
File Number)
|
|
Identification No.) |
| |
|
|
|
|
10210 Genetic Center Drive
|
|
|
|
|
San Diego, CA
|
|
|
|
92121 |
(Address of Principal Executive Offices)
|
|
|
|
(Zip Code) |
(858) 410-8000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 2.02 Results of Operations and Financial Condition.
On May 1, 2007, Gen-Probe Incorporated issued a news release announcing its financial results
for the fiscal quarter ended March 31, 2007. A copy of this news release is attached hereto as
Exhibit 99.1.
The information furnished pursuant to this Current Report, including Exhibit 99.1, shall not
be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liability of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or under the Securities
Exchange Act of 1934, as amended, regardless of any general incorporation language in any such
filing, unless Gen-Probe expressly sets forth in such filing that such information is to be
considered “filed” or incorporated by reference therein.
Item 8.01 Other Events
On April 25, 2007, Gen-Probe Incorporated and 3M Company entered into an exclusive
collaboration agreement to develop and commercialize rapid nucleic acid tests to detect certain
dangerous healthcare-associated infections.
A copy of the press release issued with respect to the execution of the agreement is furnished
with this Current Report as Exhibit 99.2.
Item 9.01. Financial Statements and Exhibits.
(d) The following exhibits are furnished with this Current Report:
99.1 News release dated May 1, 2007
99.2 News release dated April 30, 2007
Forward-Looking Statements
Any statements in this Current Report about our expectations, beliefs, plans, objectives,
assumptions or future events or performance are not historical facts and are forward-looking
statements. These statements are often, but not always, made through the use of words or phrases
such as believe, will, expect, anticipate, estimate, intend, plan and would. For example,
statements concerning Gen-Probe’s financial condition, possible or expected results of operations,
regulatory approvals, future milestone payments, growth opportunities, and plans and objectives of
management are all forward-looking statements. Forward-looking statements are not guarantees of
performance. They involve known and unknown risks, uncertainties and assumptions that may cause
actual results, levels of activity, performance or achievements to differ materially from those
expressed or implied. For additional information about risks and uncertainties we face and a
discussion of our financial statements and footnotes, see documents we file with the SEC, including
our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no
obligation and expressly disclaim any duty to update forward-looking statements to reflect events
or circumstances after the date of this Current Report or to reflect the occurrence of subsequent
events.